<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563849</url>
  </required_header>
  <id_info>
    <org_study_id>HWA486_4021</org_study_id>
    <nct_id>NCT00563849</nct_id>
  </id_info>
  <brief_title>Leflunomide + Methotrexate in Rheumatoid Arthritis</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of the combination of leflunomide and methotrexate for
      treating active rheumatoid arthritis (RA) in an open noncomparative multicenter trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point was a 20% improvement in the American College of Rheumatology criteria (ACR 20) at 20 weeks</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">74</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.</description>
    <other_name>ARAVA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between ages of 18 and 75 years old.

          -  Female subjects must be of nonchildbearing potential (i.e., surgically sterile or at
             least 2 years postmenopausal) OR their participation is contingent upon the following:

          -  They are practicing a medically accepted contraceptive regimen (acceptable methods
             must include one of the following: systemic contraceptive, oral or implanted
             estrogen/progestin; diaphragm with intravaginal spermicide; cervical cap; intrauterine
             device; or condom with intravaginal spermicide) AND

          -  they are demonstrated not to be pregnant (by serum pregnancy test) or breast-feeding
             at the time of study entry AND

               -  they intend to continue the contraceptive regimen and remain not pregnant
                  throughout the study AND

               -  they are willing to undergo pregnancy testing (serum) at screening and (urine)
                  monthly thereafter AND

               -  they are fully informed as to the risks of entering the trial and provide written
                  consent to enter the trial; female patients not sexually active should also be
                  adequately informed about appropriate methods of contraception AND

               -  they agree to not get pregnant for 24 months after discontinuation of treatment
                  with study medication or they undergo a washout procedure with cholestyramine or
                  charcoal.

          -  Male subjects must consent to practice contraception during the study. The subject
             needs to have clinically diagnosed rheumatoid arthritis including diagnosis of RA by
             ACR criteria greater than or = to 6 months prior to enrollment active disease by ACR
             criteria . Men wishing to father a child should consider discontinuing use of study
             drug and taking cholestyramine 8 gm 3 times daily for 11 days. In addition, males
             should consider discontinuation of methotrexate treatment and waiting an additional
             three months.

          -  Active disease by ACR criteria despite methotrexate therapy for three of the following
             four criteria:

               -  greater than or = to 9 tender joints

               -  greater than or = to 6 swollen joints

               -  greater than or = to 45 minutes of morning stiffness

               -  ESR greater than or = to 28mm/hr

                    -  Subject must remain on unchanged doses of NSAIDs for at least 4 weeks prior
                       to study drug administration and throughout the timecourse of the study.

                    -  Concomitant therapy will be permitted with corticosteroids at a dose of less
                       than or = to 10 mg prednisone daily (or the steroid equivalent administered
                       orally), provided the dose has been stable for at least 4 weeks prior to the
                       study drug administration; dose must remain constant throughout the
                       timecourse of the study.

                    -  Subjects must not receive intramuscular, intra-articular or intravenous
                       corticosteroids within 4 weeks prior to initiating study participation or
                       during the study.

                    -  Subjects must be able and willing to comply with the terms of this protocol.
                       Informed consent must be obtained for all subjects before enrollment in the
                       study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choe Seong Choon</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>December 3, 2007</last_update_submitted>
  <last_update_submitted_qc>December 3, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

